Endometriosis Patients Undergoing Quinagolide Treatment

This study has been completed.
Sponsor:
Information provided by:
Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier:
NCT00625950
First received: February 20, 2008
Last updated: January 9, 2009
Last verified: January 2009

February 20, 2008
January 9, 2009
February 2008
April 2008   (final data collection date for primary outcome measure)
observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00625950 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Endometriosis Patients Undergoing Quinagolide Treatment
Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
  • Hyperprolactinemia
  • Endometriosis
Procedure: ENDOMETRIAL BIOPSY
Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
Not Provided
Gómez R, Abad A, Delgado F, Tamarit S, Simón C, Pellicer A. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril. 2011 Mar 1;95(3):882-8.e1. Epub 2010 Nov 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
May 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hyperprolactinemia
  • Unexplained infertility
  • Endometriosis
Female
18 Years to 37 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00625950
VLC-AP-10208-208-1
No
Prof. Dr. Antonio Pellicer, Instituto Valenciano de Infertilidad, Spain
Instituto Valenciano de Infertilidad, Spain
Not Provided
Not Provided
Instituto Valenciano de Infertilidad, Spain
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP